Efficacy of Suxiao Jiuxin Pill on Coronary Heart Disease: A Meta-Analysis of Randomized Controlled Trials

被引:19
|
作者
Ren, Li [1 ]
Wang, Jie [1 ]
Feng, Ling [1 ]
Wang, Shuli [1 ]
Li, Jun [1 ]
机构
[1] China Acad Chinese Med Sci, Guanganmen Hosp, Dept Cardiovasc, Beijing 100053, Peoples R China
关键词
ATRIAL-FIBRILLATION; LIGUSTICUM-CHUANXIONG; PREVALENCE;
D O I
10.1155/2018/9745804
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Suxiao jiuxin pill is considered an effective ancillary drug in patients with coronary heart disease. Although numerous small, single-center clinical trials have been conducted, the benefits and harms of suxiao jiuxin pill remain controversial. We performed a meta-analysis to clarify the efficacy of suxiao jiuxin pill on patients with coronary heart disease. Randomized controlled trials were identified by using the Cochrane Library, PubMed, Web of Science, Embase, Wanfang, Weipu, and China Knowledge Resource Integrated databases (until June 2016). Pooled relative risks (RR), weighted mean differences (WMD), and 95% confidence intervals (95% CIs) were estimated using random-effects models. Forty-one trials involving 6276 patients were included in our analysis. Administration of suxiao jiuxin pill significantly improved electrocardiogram (ECG) results when compared with other therapies (RR 1.32, 95% CI 1.26 to 1.38, and P < 0.001). Subgroup analyses revealed that suxiao jiuxin pills improve ECG results more than salvia tablets (RR 1.54, 95% CI 1.41 to 1.67, and P < 0.001), isosorbide dinitrate (RR 1.14, 95% CI 1.21 to 1.44, and P = 0.001), nitroglycerin (RR 1.35, 95% CI 1.16 to 1.56, and P < 0.001), and other drugs (RR 1.32, 95% CI 1.21 to 1.44, and P < 0.001). Available evidence additionally suggests that suxiao jiuxin pills could significantly reduce total cholesterol (WMD -0.62 mmol/L, 95% CI -1.06 to -0.18 mmol/L, and P = 0.005) and low-density lipoprotein (LDL) levels (WMD -1.12 mmol/L, 95% CI -1.42 to -0.82 mmol/L, and P < 0.001) and increase high-density lipoprotein (HDL) levels (WMD 0.32 mmol/L, 95% CI 0.07 to 0.58 mmol/L, and P = 0.014). However, no significant differences were observed in total triglyceride levels, plasma viscosity, hematocrit, and fibrinogen. No incidences of adverse reactions were observed after administration of suxiao jiuxin pill. Improvements in ECG results and lipid profiles were also observed after suxiao jiuxin administration compared to other therapies. It also decreased low-cut and high-cut whole blood viscosity without significant adverse reactions.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] The protective effect of suxiaojiuxin pill on coronary heart disease: a meta-analysis of randomized controlled trials
    Ge, Zhongchun
    Ying, Jie
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (06): : 8843 - 8853
  • [2] Effectiveness and safety of Suxiao Jiuxin pill in treating acute coronary syndrome: a systematic review and Meta-analysis
    Liu Chao
    Duan Lian
    Huang Mingyan
    Li Jun
    Xiong Xingjiang
    Chen Guang
    He Haoqiang
    Zhang Zhenpeng
    Wang Jie
    Journal of Traditional Chinese Medicine, 2020, 40 (04) : 518 - 529
  • [3] Effectiveness and safety of Suxiao Jiuxin pill in treating acute coronary syndrome: a systematic review and Meta-analysis
    Liu Chao
    Duan Lian
    Huang Mingyan
    Li Jun
    Xiong Xingjiang
    Chen Guang
    He Haoqiang
    Zhang Zhenpeng
    Wang Jie
    JOURNAL OF TRADITIONAL CHINESE MEDICINE, 2020, 40 (04) : 518 - 529
  • [4] Colchicine for Coronary Heart Disease: A Meta-Analysis of Randomized Controlled Trials
    Liao, Chunfeng
    Liu, Ping
    Zhou, Yun
    Lu, Di
    Wu, Qi
    HEART SURGERY FORUM, 2021, 24 (05): : E863 - E867
  • [5] Colchicine and coronary heart disease risks: A meta-analysis of randomized controlled clinical trials
    Ma, Zijun
    Chen, Jun
    Jin, Kaiqin
    Chen, Xin
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [6] Efficacy and safety of Shexiang Baoxin Pill for stable coronary artery disease: A systematic review and meta-analysis of 42 randomized controlled trials
    Wei, Jingjing
    Ma, Teng
    Zhou, Cheng
    Hao, Pengle
    Li, Bin
    Wang, Xinlu
    Yu, Rui
    Zhu, Mingjun
    Wang, Yongxia
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [7] The efficacy of vericiguat for heart failure: A meta-analysis of randomized controlled trials
    Ma, Guofang
    Pan, Yuefang
    Qu, Chaoyi
    Li, Feng
    MEDICINE, 2023, 102 (21) : E33807
  • [8] Efficacy, safety, and economy of shensongyangxin capsules for the treatment of coronary heart disease arrhythmia: a meta-analysis of randomized controlled trials
    Ma, Luyao
    Li, Libing
    Ma, Fujin
    Ma, Fuyun
    Ma, Shujia
    ANNALS OF MEDICINE AND SURGERY, 2023, 85 (10): : 4989 - 5000
  • [9] Xinkeshu for coronary heart disease complicated with anxiety or depression: A meta-analysis of randomized controlled trials
    Liu, Qian
    Wang, Mengxi
    Wang, Haiyan
    Xie, Haitao
    Han, Jie
    Chen, Jiandong
    Yu, Peng
    Shen, Le
    Li, Yehui
    Tian, Ruina
    Chen, Xiaohu
    JOURNAL OF ETHNOPHARMACOLOGY, 2023, 312
  • [10] Fish oils in the care of coronary heart disease patients: a meta-analysis of randomized controlled trials
    Yzebe, D
    Lievre, M
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 (05) : 581 - 592